These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 34744983)

  • 1. Serum Aquaporin 4-Immunoglobulin G Titer and Neuromyelitis Optica Spectrum Disorder Activity and Severity: A Systematic Review and Meta-Analysis.
    Liu J; Tan G; Li B; Zhang J; Gao Y; Cao Y; Jia Z; Sugimoto K
    Front Neurol; 2021; 12():746959. PubMed ID: 34744983
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
    Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
    Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
    Schindler P; Grittner U; Oechtering J; Leppert D; Siebert N; Duchow AS; Oertel FC; Asseyer S; Kuchling J; Zimmermann HG; Brandt AU; Benkert P; Reindl M; Jarius S; Paul F; Bellmann-Strobl J; Kuhle J; Ruprecht K
    J Neuroinflammation; 2021 May; 18(1):105. PubMed ID: 33933106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between severe attacks and serum aquaporin-4 antibody titer in neuromyelitis optica spectrum disorder.
    Wang R; Sun D; Wang X; Shi Z; Kong L; Du Q; Zhang Y; Chen H; Luo W; Zhang N; Zhou H
    J Neurol; 2024 Jul; 271(7):4503-4512. PubMed ID: 38703259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Actual issues of serum aquaporin-4 autoantibodies evaluation in the diagnostics of neuromyelitis optica spectrum disorders].
    Krasnov VS; Totolyan NA; Nazarov VD; Mazing AV; Makshakov GS; Lapin SV; Evdoshenko EP; Skoromets AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(7. Vyp. 2):24-31. PubMed ID: 32844626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis optica spectrum disorders (NMOSD).
    Akaishi T; Takahashi T; Nakashima I; Abe M; Ishii T; Aoki M; Fujihara K
    J Neurol Sci; 2020 Mar; 410():116671. PubMed ID: 31927341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secreted aminoacyl-tRNA synthetase-interacting multifunctional protein-1 (AIMP1) is a promising predictor for the severity of acute AQP4-IgG positive neuromyelitis optica spectrum disorder.
    Yuan C; Liu X; Cai S; Zhang L; Guo R; Jia Z; Sun Y; Li B
    Mult Scler Relat Disord; 2023 Feb; 70():104504. PubMed ID: 36623394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD.
    Jitprapaikulsan J; Fryer JP; Majed M; Smith CY; Jenkins SM; Cabre P; Hinson SR; Weinshenker BG; Mandrekar J; Chen JJ; Lucchinetti CF; Jiao Y; Segan J; Schmeling JE; Mills J; Flanagan EP; McKeon A; Pittock SJ
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 35413004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study.
    Kessler RA; Mealy MA; Jimenez-Arango JA; Quan C; Paul F; López R; Hopkins S; Levy M
    Mult Scler Relat Disord; 2017 Oct; 17():198-201. PubMed ID: 29055457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia.
    Fabis-Pedrini MJ; Bundell C; Wee CK; Lucas M; McLean-Tooke A; Mastaglia FL; Carroll WM; Kermode AG
    J Neuroimmunol; 2018 Nov; 324():76-80. PubMed ID: 30248527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal evaluation of clinical characteristics of Chinese neuromyelitis optica spectrum disorder patients with different AQP4-IgG serostatus.
    Zhang X; Liu X; Yu H; Deng B; Zhang Y; Chen X
    Mult Scler Relat Disord; 2022 Jun; 62():103786. PubMed ID: 35429818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the long-term treatment of neuromyelitis optica spectrum disorder.
    Anderson M; Levy M
    J Cent Nerv Syst Dis; 2024; 16():11795735241231094. PubMed ID: 38312734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuromyelitis optica: Clinical course and potential prognostic indicators.
    Masha N; Kimbrough DJ; Eckstein CP; Hudak NM; Skeen MB; Hartsell FL; Lutz MW; Shah S
    Mult Scler Relat Disord; 2023 Jan; 69():104414. PubMed ID: 36463620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
    Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
    JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregnancy-Related Attack in Neuromyelitis Optica Spectrum Disorder With AQP4-IgG: A Single-Center Study and Meta-Analysis.
    Deng S; Lei Q; Lu W
    Front Immunol; 2021; 12():800666. PubMed ID: 35069584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AQP4-IgG-positive neuromyelitis optica spectrum disorder and temporally detected neoplasms: case report and systematic review.
    Apiraksattayakul N; Songwisit S; Owattanapanich W; Tisavipat N; Siritho S; Prayoonwiwat N; Rattanathamsakul N; Jitprapaikulsan J
    Mult Scler Relat Disord; 2022 Dec; 68():104212. PubMed ID: 36242805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab.
    Bennett JL; Fujihara K; Kim HJ; Marignier R; O'Connor KC; Sergott RC; Traboulsee A; Wiendl H; Wuerfel J; Zamvil SS; Anania VG; Buffels R; Künzel T; Lekkerkerker AN; Lennon-Chrimes S; Pittock SJ
    Front Neurol; 2023; 14():1114667. PubMed ID: 36873431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokines and Tissue Damage Biomarkers in First-Onset Neuromyelitis Optica Spectrum Disorders: Significance of Interleukin-6.
    Wei Y; Chang H; Li X; Wang H; Du L; Zhou H; Xu W; Ma Y; Yin L; Zhang X
    Neuroimmunomodulation; 2018; 25(4):215-224. PubMed ID: 30544111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of plasma sPD-1 and sPD-L1 with disease status and future relapse in AQP4-IgG (+) NMOSD.
    Liu J; Shao X; Fan J; Wang Y; Cao Y; Tan G; Sugimoto K; Li B; Jia Z
    Ann Clin Transl Neurol; 2024 Feb; 11(2):436-449. PubMed ID: 38069466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of the 2015 neuromyelitis optica spectrum disorders diagnostic criteria in a cohort of Chinese patients.
    He M; Wu L; Huang D; Yu S
    Mult Scler Relat Disord; 2020 Nov; 46():102459. PubMed ID: 32853894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.